Matinas reports oral LNC-oligonucleotides show TNFα reduction in colitis model; psoriasis markers improve

Matinas BioPharma Holdings, Inc.

Orally LNC-formulated small oligonucleotide targeting TNFα reduced serum TNFα by 37% in DSS-induced colitis model.
Active LNC formulation significantly improved clinical disease activity scores at key time points in colitis study.
In IMQ-induced psoriasis model, LNC-delivered IL-17A oligonucleotide lowered skin tissue IL-17A mRNA and improved redness/scaling.
Plans to present additional tissue/histologic analyses at future scientific meetings.
CEO highlights potential for oral delivery of extra-hepatic small oligonucleotides as differentiating platform feature.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.